{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:34:54Z","timestamp":1785861294454,"version":"3.56.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1097\/01.mph.0000212965.52759.1c","type":"journal-article","created":{"date-parts":[[2006,8,15]],"date-time":"2006-08-15T05:52:17Z","timestamp":1155621137000},"page":"513-524","source":"Crossref","is-referenced-by-count":64,"title":["Mitotane Associated With Cisplatin, Etoposide, and Doxorubicin in Advanced Childhood Adrenocortical Carcinoma"],"prefix":"10.1097","volume":"28","author":[{"given":"Patr\u00edcia","family":"Zancanella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara A. D.","family":"Pianovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Br\u00e1s H.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Ferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gislaine C.","family":"Piovezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leniza L.","family":"Lichtvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suely Z.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rvio T\u00falio","family":"Stinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz G.","family":"Callefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme A.","family":"Parise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Helena A.","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonald C.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210227","first-page":"2027","article-title":"Childhood adrenocortical tumors","volume":"82","author":"Sandrini","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-5-20210227","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.20624","article-title":"Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil","volume":"47","author":"Pianovski","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R3-5-20210227","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ejca.2004.01.031","article-title":"Childhood adrenocortical tumours","volume":"40","author":"Ribeiro","year":"2004","journal-title":"Eur J Cancer"},{"key":"R4-5-20210227","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1200\/JCO.2004.08.085","article-title":"Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry","volume":"22","author":"Michalkiewicz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R5-5-20210227","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/pbc.20318","article-title":"Biology, clinical characteristics, and management of adrenocortical tumors in children","volume":"45","author":"Rodriguez-Galindo","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"R6-5-20210227","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3","article-title":"Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer","volume":"83","author":"Berruti","year":"1998","journal-title":"Cancer"},{"key":"R7-5-20210227","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0929-693X(96)81300-5","article-title":"Corticosurr\u00e9nalomes de l'enfant: analyse r\u00e9trospective de 54 cas","volume":"3","author":"Teinturier","year":"1996","journal-title":"Arch Pediatr"},{"key":"R8-5-20210227","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/(SICI)1096-911X(199902)32:2<106::AID-MPO7>3.0.CO;2-J","article-title":"Clinical and prognostic aspects of adrenocortical neoplasms in childhood","volume":"32","author":"Teinturier","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"R9-5-20210227","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/0303-8467(92)90020-4","article-title":"Reversible mental deterioration and neurologial disturbances with o,p'-DDD therapy","volume":"94","author":"Bollen","year":"1992","journal-title":"Clin Neurol Neurosurg"},{"key":"R10-5-20210227","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00258213","article-title":"Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment","volume":"7","author":"Moolenaar","year":"1981","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-5-20210227","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N Engl J Med"},{"key":"R12-5-20210227","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"key":"R13-5-20210227","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/jps.2600631113","article-title":"Aromatic hydorxylation and alkyl oxidation in metabolism of mitotane (o,p'-DDD) in humans","volume":"63","author":"Reif","year":"1974","journal-title":"J Pharm Sci"},{"key":"R14-5-20210227","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jps.2600840203","article-title":"Metabolic activation and binding of mitotane in adrenal cortex homogenates","volume":"84","author":"Cai","year":"1995","journal-title":"J Pharm Sci"},{"key":"R15-5-20210227","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1590\/S0100-879X2000001000009","article-title":"Conventional and novel strategies in the treatment of adrenocortical cancer","volume":"33","author":"Schteingart","year":"2000","journal-title":"Braz J Med Biol Res"},{"key":"R16-5-20210227","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0277-5379(84)90033-6","article-title":"The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring","volume":"20","author":"van Slooten","year":"1984","journal-title":"Eur J Cancer Clin Oncol"},{"key":"R17-5-20210227","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"R18-5-20210227","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/PL00002218","article-title":"Therapie des Nebennierenrindenkarzinoms mit Lysodren (o,p'-DDD) Erfahrungen mit der Therapiesteuerung durch Monitoring der Serumspiegel von o,p'-DDD","volume":"96","author":"Heilmann","year":"2001","journal-title":"Med Klin (Munich)"},{"key":"R19-5-20210227","first-page":"2234","article-title":"Low-dose monitored mitotane treatment achieves the therapeutic range with managable side effects in patients with adrenocortical cancer","volume":"85","author":"Terzolo","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-5-20210227","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/cncr.10487","article-title":"A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist","volume":"94","author":"Abraham","year":"2002","journal-title":"Cancer"},{"key":"R21-5-20210227","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2265.1989.tb00453.x","article-title":"Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma","volume":"31","author":"Hague","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R22-5-20210227","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1530\/acta.0.1240526","article-title":"Mitotane increases the blood levels of hormone-binding proteins","volume":"124","author":"van Seters","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"R23-5-20210227","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2265.1987.tb01171.x","article-title":"The effect of o,p'-DDD on adrenal steroid replacement therapy requirements","volume":"27","author":"Robinson","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R24-5-20210227","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W","article-title":"Adrenocortical carcinoma: clinical and laboratory observations","volume":"88","author":"Wajchenberg","year":"2000","journal-title":"Cancer"},{"key":"R25-5-20210227","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/jpsu.2001.22280","article-title":"Adrenocortical tumors in children","volume":"36","author":"Ciftci","year":"2001","journal-title":"J Pediatr Surg"},{"key":"R26-5-20210227","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1590\/S0004-27302004000500010","article-title":"Childhood adrenocortical tumors","volume":"48","author":"Pereira","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"R27-5-20210227","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00007691-199906000-00020","article-title":"Determination of Mitotane (op-DDD) and its metabolites o,p-DDA and o,p-DDE in plasma by high performance liquid chromatography","volume":"21","author":"Andersen","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R28-5-20210227","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00007691-199510000-00015","article-title":"A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma","volume":"17","author":"Andersen","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R29-5-20210227","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1073\/pnas.161479898","article-title":"An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma","volume":"98","author":"Ribeiro","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"R30-5-20210227","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.2004.030551","article-title":"Penetrance of adrenocortical tumors associated with the germline TP53 R337H mutation","volume":"43","author":"Figueiredo","year":"2006","journal-title":"J Med Genet"},{"key":"R32-5-20210227","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0277-5379(91)90233-4","article-title":"Prolonged bleeding time due to mitotane therapy","volume":"27","author":"Haak","year":"1991","journal-title":"Eur J Cancer"},{"key":"R33-5-20210227","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R35-5-20210227","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.1998.530","article-title":"Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM","volume":"4","author":"Bonacci","year":"1998","journal-title":"Br J Cancer"},{"key":"R36-5-20210227","first-page":"117","article-title":"Experience with adrenocortical neoplasms in childhood","volume":"53","author":"Neblett","year":"1987","journal-title":"Am Surg"},{"key":"R37-5-20210227","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1590\/S0100-879X2000001000008","article-title":"Clinical results of the use of mitotane for adrenocortical carcinoma","volume":"33","author":"Kasperlik-Zaluska","year":"2000","journal-title":"Braz J Med Biol Res"},{"key":"R38-5-20210227","first-page":"502","article-title":"Adrenocortical carcinoma","volume":"57","author":"Decker","year":"1991","journal-title":"Am Surg"},{"key":"R39-5-20210227","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"key":"R40-5-20210227","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00268-001-0034-3","article-title":"Genetic background of adrenocortical tumor development","volume":"25","author":"Kjellman","year":"2001","journal-title":"World J Surg"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003453-200649090-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:41:39Z","timestamp":1785858099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-200608000-00005"}},"subtitle":["Mitotane Monitoring and Tumor Regression"],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mph.0000212965.52759.1c","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}